Health
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Patients regain weight after stopping Eli Lilly's Zepbound, study says
Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. The data, which represents the full results from an […]
Read More
Flying solo without Cigna will keep Humana focused on 2 big priorities in the year ahead
It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna will […]
Read More
Cigna shares jump on reports of abandoned Humana buyout, plans for $10 billion stock buyback
Sopa Images | Lightrocket | Getty Images Shares of Cigna jumped Monday following reports that the health-care giant has scrapped its plans to buy rival Humana due to disagreements on price, putting an early end to what would have been one of the largest deals of the decade. Cigna late Sunday also announced plans to […]
Read More
Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs
In Las Vegas, Lazaro Hernandez was a flamboyant, jet-setting poker player shown in televised tournaments with stacks of colorful chips. But the casually dressed gambler spotted on security cameras with wads of cash at the casino cage was hiding a secret life. And federal investigators say he was gambling with people’s lives. Hernandez, they say, […]
Read More
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
Blood sample tube with blood for Sickle Cell Screen -Test. Sickle cell blood test, abnormal hemoglobin test. Md Babul Hosen | Istock | Getty Images The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after […]
Read More
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
At age 19, Joe Tsogbe underwent his first hip replacement. In his 20s, he averaged about nine hospitalizations a year. By his 30s, that rose to more than a dozen. All the result of sickle cell disease, an inherited blood disorder where a genetic mutation causes normally full-moon shaped red blood cells to form into […]
Read More
Biden administration delays ban on menthol cigarettes until 2024
The Biden administration has once again delayed banning menthol cigarettes, infuriating officials of public health groups who say the products are responsible for taking hundreds of thousands of American lives. On Wednesday, the White House quietly updated its Office of Information and Regulatory Affairs website to reflect that any final ban on menthol wouldn’t take place until at […]
Read More
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
A sign stands outside a Abbvie facility in Cambridge, Massachusetts, May 20, 2021. Brian Snyder | Reuters AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it expects to complete the acquisition in […]
Read More
Senators launch bipartisan probe of private equity's growing role in U.S. health care
Two U.S. senators have launched a bipartisan investigation into secretive and powerful private-equity firms’ involvement in health care in the nation, demanding documents and information from executives associated with two hospital systems to assess how much profit they have generated through their complex financial arrangements and whether the deals harmed patients and clinicians. Sheldon Whitehouse, […]
Read More